Adiponectin deficiency: Role in chronic inflammation induced colon cancer

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1822, Issue 4, 2012, Pages 527-536

  Saxena, Arpit ^a   Chumanevich, Alexander ^a   Fletcher, Emma ^a   Larsen, Bianca ^a   Lattwein, Kirby ^a   Kaur, Kamaljeet ^a   Fayad, Raja ^a  

^a UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Adiponectin; Cancer; Colon; Inflammation

Indexed keywords

1,2 DIMETHYLHYDRAZINE; ADENYLATE KINASE; ADIPONECTIN; CYCLOOXYGENASE 2; DEXTRAN SULFATE; STAT3 PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER LOCALIZATION; CELL INFILTRATION; CHRONIC INFLAMMATION; COLITIS; COLON CANCER; CONTROLLED STUDY; DIARRHEA; DOWN REGULATION; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; OCCULT BLOOD; PRIORITY JOURNAL; PROTEOMICS; UPREGULATION; WEIGHT REDUCTION; WESTERN BLOTTING;

ADENYLATE KINASE; ADIPONECTIN; ANIMALS; CHRONIC DISEASE; COLONIC NEOPLASMS; CYCLOOXYGENASE 2; ENZYME-LINKED IMMUNOSORBENT ASSAY; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MALE; MICE; MICE, KNOCKOUT; STAT3 TRANSCRIPTION FACTOR;

MUS;

EID: 84856292522     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2011.12.006     Document Type: Article

References (50)

1. Itzkowitz S.H., Yio X. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am. J. Physiol. Gastrointest. Liver Physiol. 2004, 287:G7-G17.
2. Guthrie E., Jackson J., Shaffer J., Thompson D., Tomenson B., Creed F. Psychological disorder and severity of inflammatory bowel disease predict health-related quality of life in ulcerative colitis and Crohn's disease. Am. J. Gastroenterol. 2002, 97:1994-1999.
3. Whelan G. Ulcerative colitis-what is the risk of developing colorectal cancer?. Aust. N. Z. J. Med. 1991, 21:71-77.
4. Munkholm P. Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease. Aliment. Pharmacol. Ther. 2003, 18(Suppl. 2):1-5.
5. Seril D.N., Liao J., Yang G.Y., Yang C.S. Oxidative stress and ulcerative colitis-associated carcinogenesis: studies in humans and animal models. Carcinogenesis 2003, 24:353-362.
6. Eaden J.A., Abrams K.R., Mayberry J.F. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001, 48:526-535.
7. Giovannucci E., Ascherio A., Rimm E.B., Colditz G.A., Stampfer M.J., Willett W.C. Physical activity, obesity, and risk for colon cancer and adenoma in men. Ann. Intern. Med. 1995, 122:327-334.
8. Berg A.H., Combs T.P., Scherer P.E. ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol. Metab. 2002, 13:84-89.
9. Weiss R., Dufour S., Groszmann A., Petersen K., Dziura J., Taksali S.E., Shulman G., Caprio S. Low adiponectin levels in adolescent obesity: a marker of increased intramyocellular lipid accumulation. J. Clin. Endocrinol. Metab. 2003, 88:2014-2018.
10. Wei E.K., Giovannucci E., Fuchs C.S., Willett W.C., Mantzoros C.S. Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. J. Natl. Cancer Inst. 2005, 97:1688-1694.
11. Larsson S.C., Wolk A. Obesity and colon and rectal cancer risk: a meta-analysis of prospective studies. Am. J. Clin. Nutr. 2007, 86:556-565.
12. Gunter M.J., Leitzmann M.F. Obesity and colorectal cancer: epidemiology, mechanisms and candidate genes. J. Nutr. Biochem. 2006, 17:145-156.
13. Calle E.E., Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat. Rev. Cancer 2004, 4:579-591.
14. Birmingham J.M., Busik J.V., Hansen-Smith F.M., Fenton J.I. Novel mechanism for obesity-induced colon cancer progression. Carcinogenesis 2009, 30:690-697.
15. Bianchini F., Kaaks R., Vainio H. Overweight, obesity, and cancer risk. Lancet Oncol. 2002, 3:565-574.
16. Blain A., Cattan S., Beaugerie L., Carbonnel F., Gendre J.P., Cosnes J. Crohn's disease clinical course and severity in obese patients. Clin. Nutr. 2002, 21:51-57.
17. Yamauchi T., Nio Y., Maki T., Kobayashi M., Takazawa T., Iwabu M., Okada-Iwabu M., Kawamoto S., Kubota N., Kubota T., Ito Y., Kamon J., Tsuchida A., Kumagai K., Kozono H., Hada Y., Ogata H., Tokuyama K., Tsunoda M., Ide T., Murakami K., Awazawa M., Takamoto I., Froguel P., Hara K., Tobe K., Nagai R., Ueki K., Kadowaki T. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat. Med. 2007, 13:332-339.
18. Yamauchi T., Kamon J., Minokoshi Y., Ito Y., Waki H., Uchida S., Yamashita S., Noda M., Kita S., Ueki K., Eto K., Akanuma Y., Froguel P., Foufelle F., Ferre P., Carling D., Kimura S., Nagai R., Kahn B.B., Kadowaki T. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat. Med. 2002, 8:1288-1295.
19. Yamauchi T., Kamon J., Ito Y., Tsuchida A., Yokomizo T., Kita S., Sugiyama T., Miyagishi M., Hara K., Tsunoda M., Murakami K., Ohteki T., Uchida S., Takekawa S., Waki H., Tsuno N.H., Shibata Y., Terauchi Y., Froguel P., Tobe K., Koyasu S., Taira K., Kitamura T., Shimizu T., Nagai R., Kadowaki T. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003, 423:762-769.
20. Kim A.Y., Lee Y.S., Kim K.H., Lee J.H., Lee H.K., Jang S.H., Kim S.E., Lee G.Y., Lee J.W., Jung S.A., Chung H.Y., Jeong S., Kim J.B. Adiponectin represses colon cancer cell proliferation via AdipoR1- and -R2-mediated AMPK activation. Mol Endocrinol 2010, 24:1441-1452.
21. Shaw R.J., Kosmatka M., Bardeesy N., Hurley R.L., Witters L.A., DePinho R.A., Cantley L.C. The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:3329-3335.
22. Carling D. The AMP-activated protein kinase cascade-a unifying system for energy control. Trends Biochem. Sci. 2004, 29:18-24.
23. Ouchi N., Kobayashi H., Kihara S., Kumada M., Sato K., Inoue T., Funahashi T., Walsh K. Adiponectin stimulates angiogenesis by promoting cross-talk between AMP-activated protein kinase and Akt signaling in endothelial cells. J. Biol. Chem. 2004, 279:1304-1309.
24. Masferrer J.L., Leahy K.M., Koki A.T., Zweifel B.S., Settle S.L., Woerner B.M., Edwards D.A., Flickinger A.G., Moore R.J., Seibert K. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res. 2000, 60:1306-1311.
25. Grossmann M.E., Nkhata K.J., Mizuno N.K., Ray A., Cleary M.P. Effects of adiponectin on breast cancer cell growth and signaling. Br. J. Cancer 2008, 98:370-379.
26. Hwang J.T., Ha J., Park O.J. Combination of 5-fluorouracil and genistein induces apoptosis synergistically in chemo-resistant cancer cells through the modulation of AMPK and COX-2 signaling pathways. Biochem. Biophys. Res. Commun. 2005, 332:433-440.
27. Bowman T., Garcia R., Turkson J., Jove R. STATs in oncogenesis. Oncogene 2000, 19:2474-2488.
28. Miyazaki T., Bub J.D., Uzuki M., Iwamoto Y. Adiponectin activates c-Jun NH2-terminal kinase and inhibits signal transducer and activator of transcription 3. Biochem. Biophys. Res. Commun. 2005, 333:79-87.
29. Darnell J.E. Validating Stat3 in cancer therapy. Nat. Med. 2005, 11:595-596.
30. Nishihara T., Baba M., Matsuda M., Inoue M., Nishizawa Y., Fukuhara A., Araki H., Kihara S., Funahashi T., Tamura S., Hayashi N., Iishi H., Shimomura I. Adiponectin deficiency enhances colorectal carcinogenesis and liver tumor formation induced by azoxymethane in mice. World J. Gastroenterol. 2008, 14:6473-6480.
31. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics. CA Cancer J. Clin. 2010, 60:277-300.
32. Fayad R., Pini M., Sennello J.A., Cabay R.J., Chan L., Xu A., Fantuzzi G. Adiponectin deficiency protects mice from chemically induced colonic inflammation. Gastroenterology 2007, 132:601-614.
33. Brakenhielm E., Veitonmaki N., Cao R., Kihara S., Matsuzawa Y., Zhivotovsky B., Funahashi T., Cao Y. Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:2476-2481.
34. Ferroni P., Palmirotta R., Spila A., Martini F., Raparelli V., Fossile E., Mariotti S., Del Monte G., Buonomo O., Roselli M., Guadagni F. Prognostic significance of adiponectin levels in non-metastatic colorectal cancer. Anticancer. Res. 2007, 27:483-489.
35. Ishikawa M., Kitayama J., Kazama S., Hiramatsu T., Hatano K., Nagawa H. Plasma adiponectin and gastric cancer. Clin. Cancer Res. 2005, 11:466-472.
36. Karmiris K., Koutroubakis I.E., Xidakis C., Polychronaki M., Voudouri T., Kouroumalis E.A. Circulating levels of leptin, adiponectin, resistin, and ghrelin in inflammatory bowel disease. Inflamm. Bowel Dis. 2006, 12:100-105.
37. Westerink J., Visseren F.L. Pharmacological and non-pharmacological interventions to influence adipose tissue function. Cardiovasc Diabetol 2011, 10:13.
38. Fujisawa T., Endo H., Tomimoto A., Sugiyama M., Takahashi H., Saito S., Inamori M., Nakajima N., Watanabe M., Kubota N., Yamauchi T., Kadowaki T., Wada K., Nakagama H., Nakajima A. Adiponectin suppresses colorectal carcinogenesis under the high-fat diet condition. Gut 2008, 57:1531-1538.
39. Dietze-Schroeder D., Sell H., Uhlig M., Koenen M., Eckel J. Autocrine action of adiponectin on human fat cells prevents the release of insulin resistance-inducing factors. Diabetes 2005, 54:2003-2011.
40. Bruun J.M., Lihn A.S., Verdich C., Pedersen S.B., Toubro S., Astrup A., Richelsen B. Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans. Am. J. Physiol. Endocrinol. Metab. 2003, 285:E527-E533.
41. van Horssen R., Ten Hagen T.L., Eggermont A.M. TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility. Oncologist 2006, 11:397-408.
42. Kapas L., Hong L., Cady A.B., Opp M.R., Postlethwaite A.E., Seyer J.M., Krueger J.M. Somnogenic, pyrogenic, and anorectic activities of tumor necrosis factor-alpha and TNF-alpha fragments. Am. J. Physiol. 1992, 263:R708-R715.
43. Carswell E.A., Old L.J., Kassel R.L., Green S., Fiore N., Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl. Acad. Sci. U. S. A. 1975, 72:3666-3670.
44. Trayhurn P., Wood I.S. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br. J. Nutr. 2004, 92:347-355.
45. Gordon J.I., Hooper L.V., McNevin M.S., Wong M., Bry L. Epithelial cell growth and differentiation. III. Promoting diversity in the intestine: conversations between the microflora, epithelium, and diffuse GALT. Am. J. Physiol. 1997, 273:G565-G570.
46. Shu R.Z., Zhang F., Wang F., Feng D.C., Li X.H., Ren W.H., Wu X.L., Yang X., Liao X.D., Huang L., Wang Z.G. Adiponectin deficiency impairs liver regeneration through attenuating STAT3 phosphorylation in mice. Lab. Invest. 2009, 89:1043-1052.
47. Li Y., de Haar C., Chen M., Deuring J., Gerrits M.M., Smits R., Xia B., Kuipers E.J., van der Woude C.J. Disease-related expression of the IL6/STAT3/SOCS3 signalling pathway in ulcerative colitis and ulcerative colitis-related carcinogenesis. Gut 2010, 59:227-235.
48. Shibata R., Sato K., Pimentel D.R., Takemura Y., Kihara S., Ohashi K., Funahashi T., Ouchi N., Walsh K. Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat. Med. 2005, 11:1096-1103.
49. Sano H., Kawahito Y., Wilder R.L., Hashiramoto A., Mukai S., Asai K., Kimura S., Kato H., Kondo M., Hla T. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res. 1995, 55:3785-3789.
50. Mikkelsen H.B., Rumessen J.J., Qvortrup K. Prostaglandin H synthase immunoreactivity in human gut. An immunohistochemical study. Histochemistry 1991, 96:295-299.